Syndrome  >>  Aptivus (tipranavir)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aptivus (tipranavir) / Boehringer Ingelheim
NCT00144287: Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

Completed
3
255
Europe
Tipranavir/Ritonavir
Boehringer Ingelheim
HIV Infections
04/06
04/06
NCT00054717: Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Completed
3
630
US, Canada, RoW
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Boehringer Ingelheim
HIV Infections
09/08
 
NCT00517192 / 2005-001866-15: Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Terminated
3
40
US, Canada, Europe, RoW
Tipranavir, Darunavir, Ritonavir
Boehringer Ingelheim
HIV Infections
09/08
 
NCT00144170: Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Completed
3
882
Europe, RoW
Tipranavir (with low dose ritonavir), Comparator protease inhibitor(CPI)/low dose ritonavir(r)
Boehringer Ingelheim
HIV Infections
10/08
 
NCT00440271 / 2005-005264-86: SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Terminated
3
33
US, Canada, Europe, RoW
tipranavir, ritonavir, Optimized Background Regimen (OBR), Nucleoside Reverse Transcriptase Inhibitors (NRTIs),, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs),, Enfuvirtide,, Maraviroc,, Raltegravir
Boehringer Ingelheim
HIV Infections
10/08
 
NCT00447902 / 2005-005023-33: Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

Terminated
3
11
US, Europe, RoW
tipranavir, ritonavir
Boehringer Ingelheim
HIV Infections
10/08
 
NCT00146328: Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

Completed
2/3
997
US, Canada, Europe, RoW
Tipranavir
Boehringer Ingelheim
HIV Infections
05/08
 

Download Options